<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>6549590</identifier>
<setSpec>0482-640X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Ruiz-Tartas, A</dc:author>
<dc:author>López Lazareno, N</dc:author>
<dc:author>Zapatero Gaviria, J</dc:author>
<dc:author>Larrad Jiménez, A</dc:author>
<dc:description xml:lang="en">The authors study the correlation existing between prolactin and E-17-beta in breast cancer. In both premenopausal and post-menopausal patients prolactin may be useful as an evolutive marker. Prolactin increases particularly as a consequence of the metastatic growth. E-17-beta shows no variation when studied during the luteal phase, diminishes after the extirpation of the primitive tumor, and augments again with metastases development. After chemotherapy the amount of E-17-beta becomes almost undetectable. No correlation was found between prolactin and E-17-beta; apparently, the prolactin increase does not depend directly from the amount of circulating estradiol, but relies on the activity of the hypothalamic-hypophyseal system. With regard to E-17-beta, this product also augments after ovariectomy, suggesting an ectopic production starting on adrenal gland precursors, perhaps modulated by prolactin.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>1984 </dc:date>
<dc:title xml:lang="es">Correlaciones entre PRL y E. 17 beta en el cáncer de mama humano.</dc:title>
<dc:title xml:lang="en">[Correlations between PRL and 17-beta-E in human breast cancer].</dc:title>
<dc:publisher>Revista espanola de oncologia</dc:publisher>
</metadata>
</record>
</pubmed-document>
